Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000792384 | SCV000931680 | likely benign | Noonan syndrome 9 | 2024-01-20 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000792384 | SCV002781115 | uncertain significance | Noonan syndrome 9 | 2021-07-06 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003235396 | SCV003933864 | likely benign | not specified | 2023-05-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004994008 | SCV005506167 | likely benign | Cardiovascular phenotype | 2024-09-27 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003965585 | SCV004778573 | likely benign | SOS2-related disorder | 2022-05-17 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |